Overview

Tech Summary

Promoter Holding

Posts

AUROPHARMA

901234567891012345678940123456789.3012345678950123456789
+40.75 (+4.66%)
The current prices are delayed.Login/Sign Upto see live prices.
Previous Close: 873.6
1D
5D
1M
3M
1Y
5Y
MAX
Today's low
901
Today's high
930
52 week low
397.2
52 week high
930
Volume
7776048
About
TECHNICAL SUMMARY
DMA(12)
₹525.23
DMA(50)
₹581.23
DMA(100)
₹618.87
DMA(200)
₹662.12
FUNDEMANTAL SUMMARY
Market Cap
₹53571.77 Cr.
Enterprise Value
₹52349.09 Cr.
No. of Shares
58.59
P/E
27.09
RoE
7.5
Debt/Equity
0.18
Valuations
PE CHART
20253035
PB CHART
1.01.21.41.61.8
Promoter Holdings
Public : 8.31%
FII : 24.13%
DII : 15.73%
Promoter : 51.83%
Others : 0%
Charts
DEBT/EQUITY
0.100.200.300.400.50
Mar, 2019Mar, 2020Mar, 2021Mar, 2022Mar, 2023
ROE VS ROCE
1015202530
Mar, 2019Mar, 2020Mar, 2021Mar, 2022Mar, 2023
ROE
ROCE
REVENUE VS PROFITABILITY (1000CR.)
510152025
Mar, 2019Mar, 2020Mar, 2021Mar, 2022Mar, 2023
Revenue
Profit
MARGINS(%)
10152025
Mar, 2019Mar, 2020Mar, 2021Mar, 2022Mar, 2023
Net Margin
Gross Margin
Posts by FrontPage Users
NewsBot-display-image
Reputation: 171,052  •  Sep 25 3:51 PM
Outlook on healthcare sector; Cipla & Sun Pharma could give 15-20% return
Outlook on healthcare sector; Cipla & Sun Pharma could give 15-20% return
ANDA approval rate has been on a steady rise post-COVID, from the low of 540 in CY21 to ~700+ annual approvals in CY23E, backed by a reduction in approval timeline and clearance of the backlog.
The Economic Times
Upvote
Comment
Share
Add a comment
J K Trading-display-image
Reputation: 1,916  •  Sep 25 4:07 AM

Small SL hit 🚫
Don't be so panic & don't make any new positions🔵
Patiently waiting ✋️ for another 2 Swings 🌀are maturely active on their zones ,
#INFY 📈
#INDUSTOWER 📈
So without their SL 🚫 or TARGET ✅️ I don't create any other basket {positions}
First ,......read more
2 Upvotes
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Sep 20 10:51 PM
Aurobindo's Andhra plant receives 1 observation from USFDA after inspection
Aurobindo's Andhra plant receives 1 observation from USFDA after inspection
Aurobindo Pharma has received a Form 483 with one observation from the US FDA after an inspection of its formulation production facility in Andhra Pradesh. The observation is procedural in nature and the company intends to respond to the FDA and work to resolve the issue promptly. A Form 483 is issued when violations of relevant acts are observed during an inspection.
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Sep 20 5:18 PM
Aurobindo Pharma arm gets one observation in US FDA inspection of Tirupati plant
Aurobindo Pharma arm gets one observation in US FDA inspection of Tirupati plant
Aurobindo Pharma said that it will respond to the US FDA within the stipulated timelines and work closely with US FDA to close the observation at the earliest.
Moneycontrol
1 Upvote
Comment
Share
Add a comment
Suriya-display-image
Reputation: 215,862  •  Sep 20 1:51 AM

AUROBINDO PHARMA making FLAG & Rectangle
buy above 908
sell below 883
Chartbusters - chart - 167675520
3 Upvotes
Comment
Share
Add a comment
J K Trading-display-image
Reputation: 1,916  •  Sep 18 2:39 AM

Let's see what's happening in it 👀
🚀 / 🚫
Chartbusters - chart - 166170966
1 Upvote
Comment
Share
Add a comment
Rahul seth-display-image
Reputation: 1,911  •  Sep 15 1:08 AM

📈 INTRADAY TRADE 📈
STOCK-: AUROBINDO PHARMA
BUY ABOVE ⬆️ @910
TARGET 🎯:-915,920,924+++
SELL BELOW ⬇️ @885
TARGET 🎯:-880,875,871+++
STOPLOSS 📈:- As Per Your Risk Limit.
Chartbusters - chart - 164680798
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Sep 7 11:03 PM
Aurobindo Pharma’s Telangana plant classified as VAI by US FDA
Aurobindo Pharma’s Telangana plant classified as VAI by US FDA
The US FDA conducted an inspection at Aurobindo Pharma Limited, Bachupally Village, Telangana from July 14-21
Moneycontrol
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Sep 4 10:06 PM
Castrol India, Aurobindo Pharma among 10 stocks with RSI trending down
Castrol India, Aurobindo Pharma among 10 stocks with RSI trending down
Explore the significance of the Relative Strength Index (RSI) in assessing stock movements as we delve into the top 10 stocks that witnessed a decline in their RSI. Discover how this crucial indicator can aid investors in making informed decisions.
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Aug 25 9:13 PM
Will evaluate all options: Aurobindo Pharma on sale of injectables business
Will evaluate all options: Aurobindo Pharma on sale of injectables business
As per reports, the promoters of the firm have started the process of selling a majority stake in its injectables business Eugia Pharma
Moneycontrol
Upvote
Comment
Share
Add a comment
Suriya-display-image
Reputation: 215,862  •  Aug 25 5:43 PM

AUROPHARMA MAKING TERIANGLE PATTERN
TRADE ON BREAKOUT SIDE
Chartbusters - chart - 142842547
1 Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Aug 25 5:11 AM
Aurobindo puts its injectables business on the block, again
Aurobindo puts its injectables business on the block, again
Aurobindo Pharma promoters have begun the process of selling a majority stake in its injectables business, Eugia Pharma Specialities, after negotiations with potential suitors failed to meet valuation expectations. The promoters have hired investment bank Moelis to manage the sale.
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Aug 24 10:53 PM
Accumulate Aurobindo Pharma; target of Rs 907: KR Choksey
Accumulate Aurobindo Pharma; target of Rs 907: KR Choksey
KR Choksey recommended accumulate rating on Aurobindo Pharma with a target price of Rs 907 in its research report dated August 24, 2023.
Moneycontrol
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Aug 22 5:33 PM
Alembic, Aurobindo Pharma recall drugs from US market
Alembic, Aurobindo Pharma recall drugs from US market
The recalls were reported in the daily US Food and Drug Administration Recall Information updates on 21 August, 2023
Moneycontrol
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Aug 21 10:36 PM
Alembic, Aurobindo recall drugs in US market
Alembic, Aurobindo recall drugs in US market
Alembic Pharmaceuticals and Aurobindo Pharma are recalling products in the US due to manufacturing problems. Alembic is recalling 82,400 bottles of Tobramycin Ophthalmic Solution due to “Failed Impurities/Degradation Specifications.” Meanwhile, Aurobindo Pharma is recalling 48 bottles of Rufinamide Tablets, in both 200 mg and 400 mg doses, due to cGMP (current good manufacturing practice) deviations, USFDA said. The batch was released prior to approval. Rufinamide tablets are used to treat seizure disorders.
The Economic Times
1 Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Aug 21 9:23 PM
Neutral Aurobindo Pharma; target of Rs 910: Motilal Oswal
Neutral Aurobindo Pharma; target of Rs 910: Motilal Oswal
Motilal Oswal recommended Neutral rating on Aurobindo Pharma with a target price of Rs 910 in its research report dated August 14, 2023.
Moneycontrol
Upvote
Comment
Share
Add a comment
Atharva Bhosale-display-image
Reputation: 0  •  Aug 18 3:37 AM
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Aug 17 3:33 PM
Aurobindo Pharma shares surge on plans to launch HIV tablet
Aurobindo Pharma shares surge on plans to launch HIV tablet
The tablet will used for the treatment of children living with HIV weighing 6 kg to 25 kg and aged at least three months.
Moneycontrol
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Aug 17 2:38 AM
Accumulate Aurobindo Pharma; target of Rs 900: Prabhudas Lilladher
Accumulate Aurobindo Pharma; target of Rs 900: Prabhudas Lilladher
Prabhudas Lilladher recommended accumulate rating on Aurobindo Pharma with a target price of Rs 900 in its research report dated August 14, 2023.
Moneycontrol
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Aug 16 8:28 PM
Aurobindo Pharma gets USFDA nod for Icatibant injection
Aurobindo Pharma gets USFDA nod for Icatibant injection
The approval granted by the US Food & Drug Administration (USFDA) is for Icatibant injection of strength 30 mg/3 mL (10 mg/mL), single-dose pre-filled syringe, Aurobindo Pharma said in a regulatory filing.
Moneycontrol
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Aug 15 9:11 PM
Breakout Stocks: Motilal Oswal, Aurobindo Pharma and ESAB India rise 15-25% in a month. How should you trade on Wednesday?
Breakout Stocks: Motilal Oswal, Aurobindo Pharma and ESAB India rise 15-25% in a month. How should you trade on Wednesday?
Stocks that were in focus include names like Motilal Oswal which closed with gains of over 3%, Aurobindo Pharma which rose over 1% to a fresh 52-week high and ESAB India which settled 3% higher on Monday.
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Aug 14 5:26 PM
Pharma and steel offer great scope in the next few quarters: N Jayakumar
Pharma and steel offer great scope in the next few quarters: N Jayakumar
"If people are focusing on export led sectors, we could have a move out of tech into pharma continuing. I think it has already begun. Strangely, the well-integrated consolidated metals and commodity players could also be in focus. Especially the well-integrated steel sector could be like a new pharma in a mini sense where the worst is taken care of."
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Aug 13 2:16 AM
Aurobindo Pharma Q1 profit up 10 pc at Rs 571 cr
Aurobindo Pharma Q1 profit up 10 pc at Rs 571 cr
With the product pipeline continuing to advance, and execution of growth drivers proceeding as planned, the company is confident that its fundamental strengths position it to create an upward trajectory, Vice-Chairman and Managing Director K Nithyananda Reddy said.
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Aug 13 12:03 AM
Aurobindo Pharma Q1 results: Net profit declines 22.5% to Rs 540 crore
Aurobindo Pharma Q1 results: Net profit declines 22.5% to Rs 540 crore
Revenue from operations came in at Rs 6,850.50 crore, up 10 percent from Rs 6,236 crore in the same quarter of the previous fiscal, the company said.
Moneycontrol
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Aug 9 11:11 PM
link
Lupin, Glenmark Pharma, 7 BSE Healthcare stocks which hit 52-week high on Wednesday
The data was sourced from BSE at 2.50 pm, and the updates from the real-time data could come with a lag. The below data also pertains only to the time at which it was taken.
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Aug 7 7:36 PM
IRFC, Lupin among 7 midcap stocks which hit new 52-week high on Monday
IRFC, Lupin among 7 midcap stocks which hit new 52-week high on Monday
The BSE MidCap index stocks reached new 52-week highs, reflecting robust market performance and investor optimism. Alkem Laboratories, Aurobindo Pharma, Lupin, and others emerged as the frontrunners, making significant strides in their respective industries.
The Economic Times
Upvote
Comment
Share
Add a comment
Kuladeep-display-image
Reputation: 1,360  •  Aug 7 6:50 PM

Morning given in watchlist
above 853.2 can go for long
Chartbusters - chart - 124590558
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Aug 7 3:43 PM
Aurobindo Pharma shares hit 52-week high on US FDA approval for drug to treat infection
Aurobindo Pharma shares hit 52-week high on US FDA approval for drug to treat infection
The company's board of directors will meet on August 12, 2023, to consider and approve the standalone and consolidated unaudited financial results of the company for the first quarter ended June 30, 2023.
Moneycontrol
Upvote
Comment
Share
Add a comment
D
Reputation: 5,512  •  Aug 4 4:13 PM

Probably topped
Entered 810 put @ 18.3
Can trade another way
Sell 840 put 32-34 1 lot
Buy 810 put 17-18.5 2 lots..
Chartbusters - chart - 122641270
Upvote
Comment
Share
Add a comment
S
Reputation: 16  •  Aug 3 6:29 PM

Aurobindo Pharma sell position...read more
Chartbusters - chart - 121576684
Upvote
Comment
Share
Add a comment
Suriya-display-image
Reputation: 215,862  •  Aug 3 5:00 PM
Post by price action trading in Chartbusters Club on FrontPage
Post by price action trading in Chartbusters Club on FrontPage
#AUROPHARMA AUROPHARMA making WEDGE PATTERNtrade on breakout side
FrontPage
6 Upvotes
Comment
Share
Add a comment
Suriya-display-image
Reputation: 215,862  •  Aug 3 2:12 AM

AUROPHARMA making WEDGE PATTERN
trade on breakout side
Chartbusters - chart - 120654726
7 Upvotes
Comment
Share
Add a comment
Harsh Doshi-display-image
Reputation: 12,171  •  Aug 2 4:34 AM


Auro pharma's formation of a falling wedge pattern indicates potential for an intraday trading opportunity. Traders should closely monitor the stock as it approaches the pattern's boundaries. A breakout above the upper trendline could signal a bullish move, while a ......read more
Chartbusters - chart - 119302700
Upvote
Comment
Share
Add a comment
Chart Hacker-display-image
Reputation: 73  •  Jul 28 10:53 PM

🛑 Weekly jackpot 🛑
✅Buy Above - 839
🎯Target - 858/ 873/ 888+
BREAKOUT Stock weekly jackpot
📝 continuous uptrend and breakout the channel 🧾
Chartbusters - chart - 116459999
Upvote
1 Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 27 4:03 PM
Aurobindo Pharma soars to 52-week high on setting up subsidiary in Russia
Aurobindo Pharma soars to 52-week high on setting up subsidiary in Russia
Aurobindo Pharma will also pour in investments worth $100 million in the new subsidiary.
Moneycontrol
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 25 7:43 PM
Aurobindo Pharma arm gets USFDA nod for Plerixafor injection
Aurobindo Pharma arm gets USFDA nod for Plerixafor injection
The approval granted by the US Food & Drug Administration (USFDA) is to manufacture and market Plerixafor Injection of strengths 24 mg/1.2 mL (20 mg/mL), single-dose vial, Aurobindo Pharma said in a regulatory filing.
Moneycontrol
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 25 7:16 PM
Aurobindo Pharma arm gets USFDA nod for Plerixafor injection
Aurobindo Pharma arm gets USFDA nod for Plerixafor injection
Aurobindo Pharma said Plerixafor injection is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM).
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 24 7:21 PM
Glenmark Pharma, Canara Bank among 10 midcap stocks which hit new 52-week high on Monday
Glenmark Pharma, Canara Bank among 10 midcap stocks which hit new 52-week high on Monday
The S&P BSE MidCap Index saw an impressive display of strength on July 24, 2023, with companies like Aurobindo Pharma, Canara Bank, and General Insurance Corporation leading the rally.
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 24 3:43 PM
Aurobindo Pharma gets 3 observations from USFDA, stock rebounds from early losses
Aurobindo Pharma gets 3 observations from USFDA, stock rebounds from early losses
The observations are procedural in nature and we will respond to the USFDA within the stipulated timelines, company said in its release.
Moneycontrol
Upvote
Comment
Share
Add a comment
Crazy Chartist-display-image
Reputation: 7,197  •  Jul 24 1:01 PM
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 21 8:51 PM
Ashok Leyland, Samvardhana Motherson among 8 BSE midcap stocks which hit new 52-week high
Ashok Leyland, Samvardhana Motherson among 8 BSE midcap stocks which hit new 52-week high
After its Q1 results, Ashok Leyland achieved a new 52-week high at Rs. 183.25 on July 21, 2023. As a major player in the automotive industry, Ashok Leyland is renowned for manufacturing commercial vehicles.
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 21 8:21 PM
Glenmark Life Sciences Q1 Results: Firm posts 25% rise in profit on API strength
Glenmark Life Sciences Q1 Results: Firm posts 25% rise in profit on API strength
The company, spun off from Glenmark Pharmaceuticals in 2019 to focus on the API business, said total revenue from operations climbed 18% to 5.87 billion rupees during the quarter, with regulated markets including the U.S., Europe and India contributing 78%.
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 21 5:11 PM
Is there a tactical trade in PSUs? Is it time to buy consumer stocks?  Sandip Sabharwal explains
Is there a tactical trade in PSUs? Is it time to buy consumer stocks? Sandip Sabharwal explains
“It is tough to define what is the best strategy in consumer stocks. Whether we keep on accumulating slowly or try to time it near over the next couple of months is something we need to see. But the overall story for consumer durables should definitely improve.”
The Economic Times
Upvote
Comment
Share
Add a comment
StoxCafe-display-image
Reputation: 7,577  •  Jul 21 3:17 PM
2 Upvotes
2 Comments
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 21 7:46 AM
Aurobindo Pharma eyes $5-B revenue in 5 years
Aurobindo Pharma eyes $5-B revenue in 5 years
Aurobindo Pharma has undergone a significant reorganisation, restructuring its operations into three subsidiaries. Eugia Pharma Specialities is dedicated to injectables and specialty oral solid dosages; Curateq Biologics focusing on vaccines, biosimilars, and peptides; Apitoria Pharma, an API division.
The Economic Times
Upvote
Comment
Share
Add a comment
Madav Trader-display-image
Reputation: 13,533  •  Jul 21 12:32 AM

#AUROPHARMA I've discovered a potential stock for intraday trading with some positive indicators. It has recently broken out of a resistance level established after 2021. On the daily chart, there is an inside candle pattern, which can be a sign of a potential trend continuation.......read more
Chartbusters - chart - 108188199
2 Upvotes
3 Comments
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 19 4:36 PM
Buy Aurobindo Pharma, target price Rs 763:  ICICI Direct
Buy Aurobindo Pharma, target price Rs 763: ICICI Direct
Aurobindo Pharma, incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 44792.08 Crore) operating in Pharmaceuticals sector.
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 19 4:16 PM
Buy Aurobindo Pharma, target price Rs 768:  Sharekhan by BNP Paribas
Buy Aurobindo Pharma, target price Rs 768: Sharekhan by BNP Paribas
Aurobindo Pharma, incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 44792.08 Crore) operating in Pharmaceuticals sector.
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 17 6:08 PM
Aurobindo Pharma’s plant in Anakapalli classified as VAI by US FDA
Aurobindo Pharma’s plant in Anakapalli classified as VAI by US FDA
The VAI status means that the US Food and Drug Administration will not take any regulatory action because the objectionable conditions if found are minor and may not qualify for any action.
Moneycontrol
1 Upvote
Comment
Share
Add a comment
Baladhiya Hardik-display-image
Reputation: 5,935  •  Jul 17 1:40 AM
1 Upvote
1 Comment
Share
Add a comment
Swing Master-display-image
Reputation: 30,486  •  Jul 16 7:39 PM

🌟Intraday Stock for tomorrow 17.07.2023🌟👇🚨
Chartbusters - chart - 102902883
1 Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 14 5:13 PM
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
Net Sales are expected to increase by 5.1 percent Y-o-Y (up 1.3 percent Q-o-Q) to Rs. 6,555.2 crore, according to Prabhudas Lilladher.
Moneycontrol
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 14 5:03 PM
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
Net Sales are expected to increase by 5.1 percent Y-o-Y (up 1.3 percent Q-o-Q) to Rs. 6,555.2 crore, according to Prabhudas Lilladher.
Moneycontrol
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 13 12:21 AM
Aurobindo Pharma arm gets USFDA nod for Sevelamer hydrochloride tablets
Aurobindo Pharma arm gets USFDA nod for Sevelamer hydrochloride tablets
Aurobindo Pharma Ltd on Wednesday said its wholly-owned subsidiary APL Healthcare has received a final approval from the US health regulator for generic Sevelamer hydrochloride tablets used to control serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. The approval granted by the USFDA to make and market Sevelamer hydrochloride is for tablets of strengths 400 mg and 800 mg, Aurobindo Pharma said.
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 11 4:48 PM
Here’s why Jyotivardhan Jaipuria of Valentis Advisors is bullish on the Pharma sector
Here’s why Jyotivardhan Jaipuria of Valentis Advisors is bullish on the Pharma sector
The pharmaceutical sector, recovering from a challenging period, is now on the upswing said Jyotivardhan Jaipuria. Jaipuria's optimism stems from both the sector's bounce back after a difficult year and the stabilization of pricing pressures in the US generic market.
Moneycontrol
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 10 3:48 PM
Aurobindo Pharma arm enters into license agreement with US company; shares fall
Aurobindo Pharma arm enters into license agreement with US company; shares fall
Under the terms of the agreement, CuraTeQ has been granted exclusive license rights to commercialise BFI-751 in all major regulated markets, certain semi-regulated, and emerging markets worldwide.
Moneycontrol
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 6 7:11 PM
Macrotech Developers, Godrej Properties and 7 other midcap stocks touch new 52-week high
Macrotech Developers, Godrej Properties and 7 other midcap stocks touch new 52-week high
Mid-sized companies in India are demonstrating strength and growth potential, as reflected in the surge witnessed by the S&P BSE MidCap index. Stocks of companies such as Abbott India, Colgate-Palmolive, Godrej Properties, and Lodha hit new 52-week highs, showcasing their market appeal and resilience.
The Economic Times
1 Upvote
1 Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 6 4:26 PM
Buy Aurobindo Pharma, target price Rs 742:  ICICI Direct
Buy Aurobindo Pharma, target price Rs 742: ICICI Direct
Aurobindo Pharma, incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 43801.84 Crore) operating in Pharmaceuticals sector.
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 5 3:33 PM
Aurobindo Pharma gains on positive Phase-3 results of breast cancer drug
Aurobindo Pharma gains on positive Phase-3 results of breast cancer drug
This phase 3 study is a multi-centre, randomized, double-blinded study involving females with metastatic HER2- positive breast cancer, company said.
Moneycontrol
Upvote
Comment
Share
Add a comment
Shashwat Jain-display-image
Reputation: 8,974  •  Jul 4 3:43 AM
2 Upvotes
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jul 3 11:41 AM
Support above 18,900 can take Nifty to 19,700: Analysts
Support above 18,900 can take Nifty to 19,700: Analysts
​Chart patterns suggest that the zone of 18,900-18,950 for the Nifty will be strong support going forward. Until the index sustains above the level of 18,900, we may witness the continuation of this strong momentum up to the level of 19,450-19,500. However, if the index slips below 18,900, profit booking up to 18,650-18,500 could be witnessed. Options data suggest a broader trading range of 18,900-19,500 for the upcoming week.
The Economic Times
6 Upvotes
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jun 30 3:33 PM
Aurobindo Pharma shares fall as subsidiary undertakes facility restructuring
Aurobindo Pharma shares fall as subsidiary undertakes facility restructuring
The share touched a 52-week high of Rs 741.40 and a 52-week low of Rs 397.30 on 28 June, 2023 and 03 February, 2023, respectively.
Moneycontrol
1 Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jun 30 12:31 PM
US FDA uncovers fresh faults at India's second-biggest drugmaker Aurobindo Pharma
US FDA uncovers fresh faults at India's second-biggest drugmaker Aurobindo Pharma
Auditors uncovered “deficient” manufacturing equipment cleaning and storage controls during a visit last month to an Aurobindo Pharma Ltd. facility in Anakapalli, eastern India, according to a FDA report obtained by Bloomberg News through a Freedom of Information Act request.
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jun 28 11:41 PM
Coforge, Godrej Properties among 8 midcap stocks which touched new 52-week highs
Coforge, Godrej Properties among 8 midcap stocks which touched new 52-week highs
The Nifty Midcap index saw multiple stocks reach new 52-week highs, demonstrating resilience amidst market uncertainties. Notable performers include Coforge, Trent, Godrej Properties, Lupin, Aurobindo Pharma, Zydus Lifesciences, Power Finance Corporation, and Aditya Birla Capital. These companies showcased strong performance, driven by factors such as navigating the digital landscape, capturing consumer demand, capitalizing on housing needs, innovative healthcare solutions, dedication to research and development, healthcare solutions, strategic investments in the power sector, and diverse financial services.
The Economic Times
Upvote
Comment
Share
Add a comment
Traders Seventh Heaven-display-image
Reputation: 15,000  •  Jun 28 8:49 PM

#AUROPHARMA : 734 from 720...Gained 14 points with just 5.5 point stoploss
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jun 28 7:16 PM
Nifty at record high! 3 Nifty500 stocks turn multibaggers, 20 up over 50% since Dec peak
Nifty at record high! 3 Nifty500 stocks turn multibaggers, 20 up over 50% since Dec peak
Commenting on Nifty scaling a new lifetime high, Santosh Meena, Head of Research, Swastika Investmart, said that the 50-stock index surged to an unprecedented all-time high on account of solid fundamentals of the Indian economy and the consistent stability in global cues witnessed recently.
The Economic Times
1 Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jun 28 7:01 PM
Next big delta in pharma to come from biosimilars: Nithya Balasubramanian
Next big delta in pharma to come from biosimilars: Nithya Balasubramanian
“For Aurobindo Pharma, our official rating is market performance. We do not recommend it from a long-term perspective. It is only a tactical recommendation for the next couple of quarters for the reasons that you just read out. In the case of Gland Pharma, Bernstein sees operational leverage.”
The Economic Times
Upvote
Comment
Share
Add a comment
Traders Seventh Heaven-display-image
Reputation: 15,000  •  Jun 28 3:56 PM
3 Upvotes
2 Comments
Share
Add a comment
tradeologic-display-image
Reputation: 4,308  •  Jun 27 2:56 PM
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jun 27 3:11 AM
Ahead of Market: 10 things that will decide D-Street action on Tuesday
Ahead of Market: 10 things that will decide D-Street action on Tuesday
Indian markets had a mixed end on Monday, with Nifty ending at 18,691, up by 0.14%, while Sensex recorded a slight dip of 62,970. However, Nifty Midcap100 registered around 1% increase. Political instability in Russia, which led to an increase in oil prices, had a negative impact on the global market. But on the domestic front, the market experienced limited downside as the pharma and auto sectors provided support. Vinod Nair, Head of Research at Geojit Financial Services, expects investor confidence to be restored in the mid and small-cap segments.
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jun 26 7:21 PM
Dr Reddy's Laboratories among 3 large cap stocks which hit new 52-week high on Monday
Dr Reddy's Laboratories among 3 large cap stocks which hit new 52-week high on Monday
Dr Reddy's Laboratories, HCL Technologies, and Aurobindo Pharma have achieved 52-week highs and solidified their positions as market leaders. Dr Reddy's Laboratories has a market capitalization of Rs 84,254.00 crore and a P/E ratio of 18.7, while HCL Technologies has a market capitalization of Rs 317,037.50 crore and a P/E ratio of 21.3. Aurobindo Pharma has a market capitalization of Rs 42,213.90 crore and a P/E ratio of 21.9, highlighting their growth potential and investor appeal. Their successes serve as a reminder of the growth potential within the BSE 100 index.
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jun 26 7:06 PM
4 BSE Midcap stocks soar to record highs on Monday. ICICI Securities, PB Fintech stand out
4 BSE Midcap stocks soar to record highs on Monday. ICICI Securities, PB Fintech stand out
Several BSE Midcap stocks achieved their 52-week high, including PB Fintech and ICICI Securities. Aurobindo Pharma showcased impressive performance with its consistent growth. PB Fintech's remarkable achievement and SJVN's success reflect the positive market outlook for midcap stocks.
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jun 26 12:36 PM
Stocks in news: TCS, HDFC Life, Shree Cement, Aurobindo Pharma, Bank of Maharashtra
Stocks in news: TCS, HDFC Life, Shree Cement, Aurobindo Pharma, Bank of Maharashtra
The European Medicines Agencys (EMA) Committee has accepted Aurobindo Pharma subsidiary CuraTeQ Biologics' request to withdraw the applications for marketing authorization of ZEFYLTI (a filgrastim biosimilar) and DYRUPEG (a pegfilgrastim biosimilar).
The Economic Times
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jun 23 7:16 PM
Aurobindo Pharma shares rise 3% after subsidiary signs license for generic version of Nilotinib Capsules
Aurobindo Pharma shares rise 3% after subsidiary signs license for generic version of Nilotinib Capsules
Shares of Aurobindo Pharma went up by 3% after the company announced that its subsidiary Eugia Pharma has signed a voluntary license with Medicines Patent Pool to create and market a generic version of Nilotinib Capsules. Aurobindo Pharmas wholly-owned subsidiary Eugia Pharma Specialities has entered a voluntary sublicensing agreement with Medicines Patent Pool to manufacture and market the drug in 44 low and middle-income countries for the treatment of chronic myeloid leukemia.
The Economic Times
Upvote
1 Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jun 23 6:28 PM
Aurobindo Pharma arm signs pact with Medicines Patent Pool to develop anti-cancer drug
Aurobindo Pharma arm signs pact with Medicines Patent Pool to develop anti-cancer drug
The sub-licensing agreement for Nilotinib capsules, originally developed by Novartis, will be in 44 low and middle-income countries (LMIC), including the seven countries where patents on the product are pending or in force, Aurobindo Pharma said in a regulatory filing.
Moneycontrol
Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jun 23 6:26 PM
Aurobindo Pharma arm signs pact with Medicines Patent Pool to develop anti-cancer drug
Aurobindo Pharma arm signs pact with Medicines Patent Pool to develop anti-cancer drug
India's Aurobindo Pharma has announced that its subsidiary Eugia Pharma Specialities has signed a voluntary sub-licensing agreement with Medicines Patent Pool to develop and market an anti-cancer drug- Nilotinib capsules. Nilotinib capsules are used for the treatment of chronic myeloid leukemia.
The Economic Times
1 Upvote
Comment
Share
Add a comment
NewsBot-display-image
Reputation: 171,052  •  Jun 23 5:53 PM
Aurobindo Pharma gains 2% on subsidiary's licence deal for leukemia drug
Aurobindo Pharma gains 2% on subsidiary's licence deal for leukemia drug
Eugia Pharma has signed a voluntary sub-licensing agreement with Medicines Patent Pool to make and sell Nilotinib capsules, originally developed by Novartis, for chronic myeloid leukemia in 44 low and middle-income countries
Moneycontrol
Upvote
Comment
Share
Add a comment
Load More Posts
Hero Img
Create your account on Frontpage
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
Stock Sentiments
86% Bullish
14% Bearish
277 live trades of Rs. 26,678,864.85
K
kevin26
 
Reputation: 0 • 
Just now
AUROPHARMA
50 Qty (S) Trade entered
A
ashwineeambhore
 
Reputation: 0 • 
Just now
AUROPHARMA NOV23 FUT
1100 Qty (B) New Trade